The Supreme Court is allowing the Trump administration to axe $783 million in federal research funding, reversing a lower ...

Thermo Fisher Scientific cut the ribbon to open a highly automated manufacturing plant in North Carolina—featuring a ...

Arena BioWorks has laid off 30% of its workers 19 months after launching with $500 million and visions of bringing the Bell ...

Lighthouse Pharmaceuticals’ plan to become a beacon of hope for Alzheimer’s disease patients has received almost $50 million ...

The Cleveland Clinic's Nathan Pennell, M.D., Ph.D., is switching to the Big Pharma realm to head up hematology and oncology ...

Gilead has become the latest pharma to strengthen its in-vivo cell therapy credentials this year, paying $350 million for CAR-T developer Interius BioTherapeutics. | Gilead has become the latest ...

More than two years after the Food and Drug Administration held a public workshop on measuring overall survival (OS) in ...

Celldex has stopped development of barzolvolimab in eosinophilic esophagitis (EoE) despite meeting its primary endpoint in a ...

Xoma Royalty is ravenous for biotechs, and the Bay Area licensing aggregator has found its next meal in Mural Oncology. | ...

Jazz Pharmaceuticals has struck a deal to bolster its epilepsy ambitions, paying Saniona $42.5 million upfront for a ...

Medtronic has agreed to not only expand the size of its board of directors, but to also task it with taking a closer look at ...

The FDA has accepted Stealth BioTherapeutics’ third new drug application for its ultra rare disease candidate, providing a ...